title: Panel of autoantibodies against multiple tumor-associated antigens for detecting gastric cancer.
abstract: Gastric cancer is the second leading cause of cancer death in the world, and effective diagnosis is extremely important for good outcome. We assessed the diagnostic potential of an autoantibody panel that may provide a novel tool for the early detection of gastric cancer. We analyzed data from patients with gastric cancer and normal controls in test and validation cohorts. Autoantibody levels were measured against a panel of six tumor-associated antigens (TAAs) by ELISA: p53, heat shock protein 70, HCC-22-5, peroxiredoxin VI, KM-HN-1, and p90 TAA. We assessed serum autoantibodies in 100 participants in the test cohort. The validation cohort comprised 248 participants. Autoantibodies to at least one of the six antigens showed a sensitivity/specificity of 49.0% (95% confidence interval [CI], 39.2-58.8%)/92.4% (95% CI, 87.2-97.6%), and 52.0% (95% CI, 42.2-61.8%)/90.5% (95% CI, 84.8-96.3%) in the test and validation cohorts, respectively. In the validation cohort, no significant differences were seen when patients were subdivided based on age, sex, depth of tumor invasion, lymph node metastasis, distant metastasis, peritoneal dissemination, or TNM stage. Patients who were positive for more than two antibodies in the panel tended to have a worse prognosis than those who were positive for one or no antibody. Measurement of autoantibody response to multiple TAAs in an optimized panel assay to discriminate patients with early stage gastric cancer from normal controls may aid in the early detection of gastric cancer.
authors.affiliation: Division of Gastroenterological Surgery, Chiba Cancer Center, Chiba, Japan.
authors.forename: Isamu
authors.initials: I
authors.lastname: Hoshino
authors.affiliation: Division of Gastroenterological Surgery, Chiba Cancer Center, Chiba, Japan.
authors.forename: Matsuo
authors.initials: M
authors.lastname: Nagata
authors.affiliation: Division of Gastroenterological Surgery, Chiba Cancer Center, Chiba, Japan.
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Takiguchi
authors.affiliation: Division of Gastroenterological Surgery, Chiba Cancer Center, Chiba, Japan.
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Nabeya
authors.affiliation: Division of Gastroenterological Surgery, Chiba Cancer Center, Chiba, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Ikeda
authors.affiliation: Division of Chemotherapy and Cancer Diagnosis, Chiba Cancer Center, Chiba, Japan.
authors.forename: Sana
authors.initials: S
authors.lastname: Yokoi
authors.affiliation: Medical & Biological Laboratories Co., Ltd, Nagoya, Japan.
authors.forename: Akiko
authors.initials: A
authors.lastname: Kuwajima
authors.affiliation: Division of Pathology and Cell Therapy, Chiba Cancer Center, Chiba, Japan.
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Tagawa
authors.affiliation: Division of Clinical Genetics and Proteomics, Department of Laboratory Medicine, Chiba University Hospital, Chiba, Japan.
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Matsushita
authors.affiliation: Department of Surgery, School of Medicine, Toho University, Tokyo, Japan.
authors.forename: Yajima
authors.initials: Y
authors.lastname: Satoshi
authors.affiliation: Department of Surgery, School of Medicine, Toho University, Tokyo, Japan.
authors.forename: Shimada
authors.initials: S
authors.lastname: Hideaki
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000276:immunology*; D001323:Autoantibodies / Q000276:immunology*; D001324:Autoantigens / Q000276:immunology; D014408:Biomarkers, Tumor / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D018840:HSP70 Heat-Shock Proteins / Q000276:immunology; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D008297:Male; D008565:Membrane Proteins / Q000276:immunology; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000276:immunology*; D009687:Nuclear Proteins / Q000276:immunology; D054465:Peroxiredoxin VI / Q000276:immunology; D011379:Prognosis; D013274:Stomach Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000401:mortality; D016159:Tumor Suppressor Protein p53 / Q000276:immunology
chemical_list: D000951:Antigens, Neoplasm; D001323:Autoantibodies; D001324:Autoantigens; D014408:Biomarkers, Tumor; C494896:CCDC110 protein, human; C500266:CIP2A protein, human; C510802:HCC-22-5 antigen, human; D018840:HSP70 Heat-Shock Proteins; D047908:Intracellular Signaling Peptides and Proteins; D008565:Membrane Proteins; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D054465:Peroxiredoxin VI
keywords: Autoantibody; gastric cancer; p53; panel; prognosis